GlassScriptPhysician profile
Matthew B Coombs
NPI 1972529725
$12,879.86
in general payments reported to CMS, 2019-2025
56 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $926 · 2021: $1,457 · 2022: $2,127 · 2023: $2,620 · 2024: $2,638 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,845.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,475.31 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $2,112.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $976.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $868.57 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $627.41 | 2019-2025 | |
| Amgen INC. | $502.42 | 2019-2025 | Repatha, Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $470.13 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $368.54 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $364.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $321.81 | 2019-2025 | Spravato, Xarelto |
| Astellas Pharma US INC | $321.49 | 2019-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.53 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $258.29 | 2020-2025 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.50 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Kowa Pharmaceuticals America, INC. | $231.04 | 2020-2025 | Livalo, Seglentis, Zoryve |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Coombs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.